FACS-assisted CRISPR-Cas9 genome editing of human induced pluripotent stem cells

Autor: Amandine Caillaud, Antoine Lévêque, Aurélie Thédrez, Aurore Girardeau, Robin Canac, Lise Bray, Manon Baudic, Julien Barc, Nathalie Gaborit, Guillaume Lamirault, Betty Gardie, Salam Idriss, Antoine Rimbert, Cédric Le May, Bertrand Cariou, Karim Si-Tayeb

Publikováno v: STAR Protocols, Vol 3, Iss 4, Pp 101680- (2022)

Summary: This manuscript proposes an efficient and reproducible protocol for the generation of genetically modified human induced pluripotent stem cells (hiPSCs) by genome editing using CRISPR-Cas9 technology. Here, we describe the experimental strat

Externí odkaz: https://doaj.org/article/5abbb31c95e14d87806374946c01203d

PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) Ex Vivo

Autor: Elise F. Villard, PhD, Aurélie Thedrez, PhD, Jorg Blankenstein, PhD, Mikaël Croyal, BSc, Thi-Thu-Trang Tran, PhD, Bruno Poirier, PhD, Jean-Christophe Le Bail, PhD, Stéphane Illiano, PhD, Estelle Nobécourt, MD, PhD, Michel Krempf, MD, PhD, Dirk J. Blom, MD, PhD, A. David Marais, MD, Philip Janiak, PhD, Anthony J. Muslin, MD, PhD, Etienne Guillot, PhD, Gilles Lambert, PhD

Publikováno v: JACC: Basic to Translational Science, Vol 1, Iss 6, Pp 419-427 (2016)

To elucidate how the proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor alirocumab modulates lipoprotein(a) [Lp(a)] plasma levels, the authors performed a series of Lp(a) uptake studies in primary human hepatocytes and dermal fibroblasts

Externí odkaz: https://doaj.org/article/a2e8609f65714b7b9f3d883bea5a8386

Identification of a Gain-of-Function

Autor: Wieneke, Dijk, Mathilde, Di Filippo, Sander, Kooijman, Robin, van Eenige, Antoine, Rimbert, Amandine, Caillaud, Aurélie, Thedrez, Lucie, Arnaud, Amanda, Pronk, Damien, Garçon, Thibaud, Sotin, Pierre, Lindenbaum, Enrique, Ozcariz Garcia, Jean-Paul, Pais de Barros, Laurence, Duvillard, Karim, Si-Tayeb, Nuria, Amigo, Jean-Yves, Le Questel, Patrick C N, Rensen, Cédric, Le May, Philippe, Moulin, Bertrand, Cariou

Publikováno v: Circulation. 146(10)

Atherosclerotic cardiovascular disease is the main cause of mortality worldwide and is strongly influenced by circulating low-density lipoprotein (LDL) cholesterol levels. Only a few genes causally related to plasma LDL cholesterol levels have been i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a768ba622130f16277ab131e547af7da
https://pubmed.ncbi.nlm.nih.gov/35978009

PCSK9 is not secreted from mature differentiated intestinal cells

Autor: Melissa Touvron, Cédric Le May, Thibaud Sotin, Xavier Prieur, L. Arnaud, Annik Prat, Anna Roubtsova, Claire Blanchard, Nabil G. Seidah, Wieneke Dijk, Audrey Ayer, Moreau François, Bertrand Cariou, Laurianne Van Landeghem, Gilliane Chadeuf, Damien Garçon, Aurélie Thedrez, Mikaël Croyal

Publikováno v: Journal of Lipid Research
Journal of Lipid Research, 2021, 62, pp.100096. ⟨10.1016/j.jlr.2021.100096⟩
Journal of Lipid Research, American Society for Biochemistry and Molecular Biology, 2021, 62, pp.100096. ⟨10.1016/j.jlr.2021.100096⟩
J Lipid Res
Journal of Lipid Research, Vol 62, Iss, Pp 100096-(2021)

International audience; Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes lysosomal degradation of the LDL receptor and is a key regulator of cholesterol metabolism. After the liver, the small intestine is the second organ that highly ex

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6566bafe98cac0f9b7560f4c63d6f516
https://hal.inrae.fr/hal-03350100

PCSK9 inhibition with alirocumab reduces lipoprotein(a) levels in nonhuman primates by lowering apolipoprotein(a) production rate

Autor: Ilya Khantalin, Stéphane Ramin-Mangata, Brice Nativel, Stéphanie Billon-Crossouard, Mikaël Croyal, Rose Hélène Blanchard, Etienne Guillot, Kévin Chemello, Michel Krempf, Valentin Blanchard, Gilles Lambert, Audrey Aguesse, Bruno Poirier, Philip Janiak, Elise F. Villard, Christophe Boixel, Jean-Christophe Le Bail, Aurélie Thedrez, Thi-Thu-Trang Tran

Publikováno v: Clinical Science
Clinical Science, Portland Press, 2018, 132 (10), pp.1075-1083. ⟨10.1042/CS20180040⟩

Therapeutic antibodies targeting proprotein convertase subtilisin kexin type 9 (PCSK9) (e.g. alirocumab) lower low-density lipoprotein cholesterol (LDL-C) and lipoprotein (a) [Lp(a)] levels in clinical trials. We recently showed that PCSK9 enhances a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::458694c8ac4928c889b310c06efa5781
https://doi.org/10.1042/cs20180040